AstraZeneca (AZN) stock gained 1% after halting its Phase III lung cancer trial. Data monitoring committee found volrustomig combo unlikely to succeed. The post AstraZeneca (AZN) Stock Edges Higher Despite Discontinuing Phase III Lung Cancer Study appeared first on Blockonomi.